Big single product combined with cross-border e-commerce is Tomson's future growth twin engine

On February 27th, Tomson Bianjian released its 2016 annual report. From January to December 2016, the company achieved operating income of 2.309 billion yuan, an increase of 1.90% over the same period of last year; net profit of 535 million yuan.

During the reporting period, Tomson Bianjian steadily promoted the requirements of the 2016 business plan, established a joint venture with NBTY to carry out global brand integration; increased brand promotion, launched new brand upgrades; focused on business, service, product innovation, and continued to build health management Content products such as solutions.

2017 is the third year in which Tomson has implemented a three-year new business plan and is also a crucial year. Tomson will build a new round of performance growth in accordance with the established strategic direction and through the construction of a large pharmaceutical industry, the launch of a large single product strategy, and the development of cross-border e-commerce.

Big single product strategy opens a new round of performance growth

Based on the long-term healthy development in the future, in 2017, Tomson will strengthen the business structure of some sub-brands, and the bone health brand will have more strength and scientific and fine Chinese herbal medicine brands can be included in the Tomson Pharmaceutical business sector, including the formation of Tomson. A large pharmaceutical system including many strengths and unlimited energy. The pharmaceutical industry system will fully integrate and utilize the advantages of channels and services to enhance the company's main brand, strong health, unlimited energy management and profitability, and provide a strong guarantee for the company's performance growth.

In order to comply with the rapid growth trend of the health care products market segment, Tomson will also open a large single product operation model this year, which is the second major market strategy after the company's endorsement.

Jianli Polyglycoside Collagen Chondroitin Calcium Tablets will be the first product to be implemented by Tomson's Big Singles strategy. The company will focus on its superior resources and make it a representative product that detonates the healthy bone market and enhance the market. Occupancy rate, sturdy large single product mode.

The successful operation of the large single product model will not only change the current situation of the lower sales of new products of Tomson Bianjian, but also break the growth slowdown after the company's 10 billion retail scale and open a new round of performance growth. At the same time, the smooth construction of Tomson's future large single products will break through the stalemate in the growth of pharmacy VMS, accelerate the cultivation and even open up new category segments, and create new market increments for distributors, retailers and other partners.

Organic Scholartree Fruits Tea

Organic Scholartree Fruits Tea,Scholartree Fruits Tea,Scholar Tree Fruit Tea,Fruit Tea

Hengshui Shanzhi Health Drink Co., Ltd , https://www.grasspowder-sz.com